Amplifying the therapeutic potential of rabbit- derived antibodies by an advanced, multi-parametric humanization approach for single-step engineering
Advancing bispecific lead generation through integrated in vivo, in vitro, and in silico approaches to optimize clinical suitability
Accelerating VHH lead candidate panel generation through high-throughput early triaging of optimal B cell clones
Maximizing VHH lead generation for therapeutic breakthroughs
Bispecific antibody discovery and characterization: from discovery through production
Humanization: rabbit mAb CDR grafting, the first step towards clinically suitable monoclonal antibodies
Register for IPA updates
By clicking submit below, you agree that IPA may store and process your personal information to send you email updates. You can find further information in our Privacy Policy.